Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease
Journal of Movement Disorders · 31.01.2023 · 16 (1) · 22-41
DOI: 10.14802/jmd.22141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Movement Disorders, erschienen am 31.01.2023. Verfasst von Young Cha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Molecular Neurobiology Laboratory, McLean Hospital and Program in Neuroscience, Harvard Medical School, Belmont, MA, USA. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting 1%–2% of the population over the age of 65. As the population ages, it is anticipated that the burden on society will significantly escalate. Although symptom reduction by currently available pharmacological and/or surgical treatments improves the quality of life of many PD patients, there are no treatments that can slow down, halt, or reverse disease progression. Because the loss of a specific cell type, midbrain dopamine neurons in the substantia nigra, is the main cause of motor dysfunction in PD, it is considered a promising target for cell replacement therapy. Indeed, numerous preclinical and clinical studies using fetal cell transplantation have provided proof of concept that cell replacement therapy may be a viable therapeutic approach for PD. However, the use of human fetal cells remains fraught with controversy due to fundamental ethical, practical, and clinical limitations. Groundbreaking work on human pluripotent stem cells (hPSCs), including human embryonic stem cells and human induced pluripotent stem cells, coupled with extensive basic research in the stem cell field offers promising potential for hPSC-based cell replacement to become a realistic treatment regimen for PD once several major issues can be successfully addressed. In this review, we will discuss the prospects and challenges of hPSC-based cell therapy for PD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Molecular Neurobiology Laboratory, McLean Hospital and Program in Neuroscience, Harvard Medical School, Belmont, MA, USA.
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
- Parkinson’s Cell Therapy Research Fund
- McLean Hospital
- Massachusetts General Hospital
- Masson Family Endowed Scholar in Neurosurgery, Massachusetts General Hospital
Zitieren
APA
Cha, Y., Park, T. Y., Leblanc, P., & Kim, K. S. (2023). Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease. Journal of Movement Disorders, 16(1), 22-41. https://doi.org/10.14802/jmd.22141
Vancouver
Cha Y, Park TY, Leblanc P, Kim KS. Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease. Journal of Movement Disorders. 2023;16(1):22-41. doi:10.14802/jmd.22141
BibTeX
@article{Cha2023,
author = {Cha, Young and Park, Tae-Yoon and Leblanc, Pierre and Kim, Kwang-Soo},
title = {Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease},
journal = {Journal of Movement Disorders},
year = {2023},
volume = {16},
number = {1},
pages = {22--41},
doi = {10.14802/jmd.22141}
}
EUVIMED